The efficacy of secobarbital sodium plus chlorpromazine (SC) in the prevention of cisplatin induced emesis was compared to the combination of metoclopramide, diphenhydramine, and dexamethasone (MDD). Twenty-three patients were entered onto protocol. Eighteen were evaluable. Good to excellent antiemetic prophylaxis was obtained in 72% with MDD versus 17% with SC (P < 0.01). Sedation and anticholinergic side effects were more common with SC. Extrapyramidal reactions were more commonly seen with MDD. Significantly more patients preferred the combination of metoclopramide, diphenhydramine, and dexa-methasone (P < 0.05). Cancer 58:959-962, 1986. HE INTRODUCTION of cisplatin into the chemother-T apeutic armamentarium gave impetus to therapeutic attempts to control the associated severe nausea and vomiting. High-dose metoclopramide was the first truly effective antiemetic regimen for cisplatin. ' This regimen has been subsequently improved2 by the addition of di-phenhydramine to prevent extrapyramidal side effects, and dexamethasone to increase the antiemetic efficacy and decrease the frequency of diarrhea. Yet metoclo-pramide is not a perfect antiemetic because of extrapy-ramidal side effect^^,^ and the high cost.5 Sevin d aL6 demonstrated the antiemetic activity of the barbiturate-phenothiazine combination of pentobar-bital sodium plus prochlorperazine with dexamethasone in patients treated with cisplatin regimens. They observed no vomiting in 22/30 (73%) patients. We postulated that barbiturates might enhance the antiemetic effect of phe-nothiazines through their sedative potential. This study was undertaken to investigate the antiemetic efficacy of the relatively inexpensive regimen of secobar
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.